Xenon Pharmaceuticals Inc.

This study tests whether an experimental drug called XEN1101 can safely reduce the number of severe, full-body seizures (tonic-clonic) in people with epilepsy. About 160 participants aged 12 and older will receive either the drug or a placebo alongside their current seizure medic…

This study tests an experimental drug called XEN1101 for people with focal-onset seizures (a type of epilepsy). About 360 adults will receive either the drug or a placebo alongside their current seizure medications. The goal is to see if XEN1101 safely reduces seizure frequency b…

This study tests an experimental drug called azetukalner for people with moderate-to-severe major depressive disorder. About 450 adults will receive either the drug or a placebo for 6 weeks. The goal is to see if the drug reduces depression symptoms and improves pleasure and inte…

This study tests a new medication called azetukalner for people with bipolar I or II disorder who are currently in a depressive episode. Researchers want to see if it reduces depression symptoms better than a placebo over 6 weeks. The trial involves 400 adults aged 18 to 74 and i…

This study tests an experimental drug called azetukalner in 450 adults with moderate-to-severe major depression. Participants take the drug or a placebo daily for 6 weeks to see if it reduces depression symptoms like low mood and loss of interest. The goal is to find a new treatm…